USA - NASDAQ:LHDX - US54948U1051 - Common Stock
The current stock price of LHDX is 0.4523 USD. In the past month the price increased by 17.18%. In the past year, price decreased by -89.13%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.07 | 226.42B | ||
| ISRG | INTUITIVE SURGICAL INC | 64.69 | 199.66B | ||
| BSX | BOSTON SCIENTIFIC CORP | 35.16 | 153.71B | ||
| SYK | STRYKER CORP | 27.79 | 139.95B | ||
| IDXX | IDEXX LABORATORIES INC | 55.07 | 55.55B | ||
| BDX | BECTON DICKINSON AND CO | 13.42 | 55.47B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.56 | 50.63B | ||
| RMD | RESMED INC | 24.85 | 35.90B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.02 | 33.58B | ||
| DXCM | DEXCOM INC | 31.8 | 23.20B | ||
| PODD | INSULET CORP | 73.53 | 23.65B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.09 | 17.78B |
Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. The company is headquartered in Emeryville, California and currently employs 221 full-time employees. The company went IPO on 2021-02-05. The firm is focused on providing disposable, single use test kit platform to replace central lab testing for diagnosing infectious diseases which leads to treatment and disease control outcomes. The firm has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. The company is also engaged in the commercialization of commercializing its PCR-quality COVID-19 test kits. Through its polymerase chain reaction (PCR)-quality technology, the Company offers single-use testing for infectious diseases. Its test kits are coupled with its digital platform, LUCI PASS, which is designed to securely deliver a clinically relevant test result to users at home, healthcare providers, and to required public health authorities. The firm has its operations in United States and Canada, among others.
LUCIRA HEALTH INC
1315 63Rd Street
Emeryville CALIFORNIA 94608 US
CEO: Erik T. Engelson
Employees: 221
Phone: 18145741546.0
Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. The company is headquartered in Emeryville, California and currently employs 221 full-time employees. The company went IPO on 2021-02-05. The firm is focused on providing disposable, single use test kit platform to replace central lab testing for diagnosing infectious diseases which leads to treatment and disease control outcomes. The firm has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. The company is also engaged in the commercialization of commercializing its PCR-quality COVID-19 test kits. Through its polymerase chain reaction (PCR)-quality technology, the Company offers single-use testing for infectious diseases. Its test kits are coupled with its digital platform, LUCI PASS, which is designed to securely deliver a clinically relevant test result to users at home, healthcare providers, and to required public health authorities. The firm has its operations in United States and Canada, among others.
The current stock price of LHDX is 0.4523 USD. The price decreased by -19.23% in the last trading session.
LHDX does not pay a dividend.
LHDX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
LUCIRA HEALTH INC (LHDX) has a market capitalization of 18.36M USD. This makes LHDX a Nano Cap stock.
LUCIRA HEALTH INC (LHDX) will report earnings on 2023-05-10.
You can find the ownership structure of LUCIRA HEALTH INC (LHDX) on the Ownership tab.
ChartMill assigns a technical rating of 5 / 10 to LHDX. When comparing the yearly performance of all stocks, LHDX is a bad performer in the overall market: 87.4% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to LHDX. LHDX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months LHDX reported a non-GAAP Earnings per Share(EPS) of -3.19. The EPS decreased by -84.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.48 |
6 analysts have analysed LHDX and the average price target is 0.77 USD. This implies a price increase of 69.14% is expected in the next year compared to the current price of 0.4523.
For the next year, analysts expect an EPS growth of 83% and a revenue growth 201.55% for LHDX